Maximilian Seles1, Florian Posch2, Georg P Pichler1, Thomas Gary3, Karl Pummer1, Richard Zigeuner1, Georg C Hutterer4, Martin Pichler5. 1. Department of Urology, Medical University of Graz, Graz, Austria. 2. Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 3. Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 4. Department of Urology, Medical University of Graz, Graz, Austria. Electronic address: g.hutterer@gmail.com. 5. Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: The average size of blood platelets determined by mean platelet volume might represent a biologically meaningful parameter in carcinogenesis and potentially serve as a novel prognostic biomarker in renal cell carcinoma. MATERIALS AND METHODS: In this retrospective analysis of the records of 652 patients we evaluated the potential prognostic value of mean platelet volume and its ability to improve existing risk assessment tools used in adjuvant clinical trials in nonmetastatic renal cell carcinoma cases. Associations of mean platelet volume with baseline covariates and clinical outcomes (recurrence, and death from renal cell carcinoma and other causes) were assessed with the competing risk estimators of Kaplan-Meier, and Marubini and Valsecchi, respectively. Univariable and multivariable Cox proportional hazard models were constructed. The Harrell c-index was applied to test improvements in the predictive accuracy of the established Leibovich prognosis score. RESULTS: Small platelet volume was associated with large tumors (p = 0.043), high Fuhrman grade (p = 0.001), sarcomatoid components (p <0.0001), histological tumor necrosis (p = 0.044) and vascular invasion (p = 0.022). On univariable and multivariable analyses small platelet volume accurately predicted recurrent renal cell carcinoma (continuously and binary coded) and cancer specific survival. Adding mean platelet volume to the Leibovich prognosis score improved its discriminative performance (c-index = 0.83, p = 0.004). CONCLUSIONS: Mean platelet volume represented a highly significant predictor of recurrence and cancer specific death in patients with renal cell carcinoma. This parameter improved the accuracy of the Leibovich prognosis score to better predict long-term outcomes in localized renal cell carcinoma cases after curative surgical resection.
PURPOSE: The average size of blood platelets determined by mean platelet volume might represent a biologically meaningful parameter in carcinogenesis and potentially serve as a novel prognostic biomarker in renal cell carcinoma. MATERIALS AND METHODS: In this retrospective analysis of the records of 652 patients we evaluated the potential prognostic value of mean platelet volume and its ability to improve existing risk assessment tools used in adjuvant clinical trials in nonmetastatic renal cell carcinoma cases. Associations of mean platelet volume with baseline covariates and clinical outcomes (recurrence, and death from renal cell carcinoma and other causes) were assessed with the competing risk estimators of Kaplan-Meier, and Marubini and Valsecchi, respectively. Univariable and multivariable Cox proportional hazard models were constructed. The Harrell c-index was applied to test improvements in the predictive accuracy of the established Leibovich prognosis score. RESULTS: Small platelet volume was associated with large tumors (p = 0.043), high Fuhrman grade (p = 0.001), sarcomatoid components (p <0.0001), histological tumor necrosis (p = 0.044) and vascular invasion (p = 0.022). On univariable and multivariable analyses small platelet volume accurately predicted recurrent renal cell carcinoma (continuously and binary coded) and cancer specific survival. Adding mean platelet volume to the Leibovich prognosis score improved its discriminative performance (c-index = 0.83, p = 0.004). CONCLUSIONS: Mean platelet volume represented a highly significant predictor of recurrence and cancer specific death in patients with renal cell carcinoma. This parameter improved the accuracy of the Leibovich prognosis score to better predict long-term outcomes in localized renal cell carcinoma cases after curative surgical resection.
Authors: Marta Masternak; Bartosz Puła; Joanna Knap; Anna Waszczuk-Gajda; Joanna Drozd-Sokołowska; Kamil Wdowiak; Sebastian Grosicki; Izabela Kozłowska; Marta Kaźmierczak; Anna Łabędź; Łukasz Szukalski; Kamil Wiśniewski; Edyta Subocz; Janusz Hałka; Agnieszka Szymczyk; Marek Hus; Krzysztof Jamroziak; Krzysztof Giannopoulos Journal: Cancer Manag Res Date: 2020-10-12 Impact factor: 3.989
Authors: Marcin Życzkowski; Paweł Rajwa; Bartłomiej Burzyński; Maciej Gaździk; Iga Florczyk; Monika Slabon-Turska; Andrzej Paradysz Journal: Arch Med Sci Date: 2019-03-25 Impact factor: 3.318
Authors: Maximilian Seles; Georg C Hutterer; Johannes Foßelteder; Marek Svoboda; Margit Resel; Dominik A Barth; Renate Pichler; Thomas Bauernhofer; Richard E Zigeuner; Karl Pummer; Ondrej Slaby; Christiane Klec; Martin Pichler Journal: Cancers (Basel) Date: 2020-05-10 Impact factor: 6.639
Authors: Marcin Życzkowski; Zbigniew Kaletka; Pawel Rajwa; Grzegorz Rempega; Paweł Stelmach; Rafał Bogacki; Olga Łach-Wojnarowicz; Ewa Paradysz Journal: Int Urol Nephrol Date: 2020-01-17 Impact factor: 2.370